BOPI 04 BR/2024 REPERTOIRE NUMERIQUE 13 (54) Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome. (72) GARIBALDI, George (CH) (73) NOEMA PHARMA AG, Barfusserplatz 3, 4051 BASEL (CH) (74) Cabinet Spoor & Fisher Inc. Ngwafor & Partners, The House of Gideon, Golf/Bastos Quater, Opposite The American Embassy, Entrance-Saint John Paul II Boulevard, P.O. Box 8211, YAOUNDE (CM). (57) Provided herein are methods of treating Tourette Syndrome in a subject in need thereof by administering to the subject compositions comprising a PDE10 inhibitor. Also disclosed are crystalline solid forms of the compound of Formula I and uses thereof : Formula I & Fig. 1 ________________________________________ (11) 21484 Consulter le mémoire (51) A61K 31/4439 (2018.01); A61K 9/48 (2018.01); A61P 25/00 (2018.01); A61P 25/08 (2018.01); A61P 25/28 (2018.01) ; A61P 35/00 (2018.01) (21) 1202200513 - PCT/EP2021/065075 (22) 04/06/2021 (30) US n° 63/035, 313 du 05/06/2020 (54) Methods of treatment of tuberous sclerosis complex. (72) GARIBALDI, George (CH) (73) NOEMA PHARMA AG, Barfusserplatz 3, 4051 BASEL (CH) (74) Cabinet Spoor & Fisher Inc. Ngwafor & Partners, The House of Gideon, Golf/Bastos Quater, Opposite The American Embassy, Entrance-Saint John Paul II Boulevard, P.O. Box 8211, YAOUNDE (CM). (57) Provided herein are methods of treating tuberous sclerosis complex in a subject in need thereof by administering to the subject compositions comprising an mGlu5 negative allosteric modulator (NAM), having the structure of Formula I :
RkJQdWJsaXNoZXIy MTM1NDc3MA==